By: Victoria Perniola

The digital health boom completely rewrote the rules of patient access, but it also opened a dangerous backdoor for bad actors. The same technology that makes treatment easier to access can also make an online storefront look like a legitimate healthcare platform, even when there is no prescriber, licensed pharmacy, or clinical infrastructure behind it.

A stark reminder of this arrived on June 23, 2026, when the FDA issued a coordinated batch of ten warning letters to online sellers of ketamine products. Buy Keta Online was one of them. The letters are not isolated enforcement actions against individual websites; taken together, they are a critical market signal. They highlight where the federal government is drawing the line as public interest in psychedelic-assisted therapies continues to surge.

According to the FDA’s reviews, the websites were introducing unapproved and misbranded ketamine products in multiple forms, including liquids, injectable vials, capsules, troches, suppositories, powders, and nasal sprays into interstate commerce. In many cases, the websites permitted consumers to purchase prescription ketamine products without a prescription.

For industry insiders, the common callouts across the FDA’s letters point to a systemic concern regarding consumer safety and regulatory circumvention and show exactly what the agency is looking at:

· Website Claims Are Regulatory Evidence: FDA repeatedly relied on the sellers’ own product pages, treatment claims, disclaimers, and checkout practices to determine how the products were intended to be used and sold. Claims involving depression, anxiety, chronic pain, anesthesia, and other medical uses can establish that a product is a drug under the FD&C Act, regardless of how the seller labels it. In one letter, FDA specifically found that “research and scientific use” and “non-clinical” disclaimers did not overcome the website’s human use claims. For operators and investors, website copy is not just marketing; it is regulatory evidence.

· FDA Approval Does Not Travel: FDA-approved ketamine is an injectable anesthetic and is not approved for psychiatric treatment, while FDA-approved esketamine nasal spray is approved for specified depression-related indications. That approval does not carry over to a compounded troche, capsule, nasal spray, suppository, powder, or other formulation simply because it contains ketamine or esketamine.

· The REMS Comparison Is a Market Signal: FDA repeatedly contrasted the cited products with the FDA-approved esketamine nasal spray, which carries boxed warnings and must be dispensed and administered in certified healthcare settings

with at least two hours of monitoring. Those REMS requirements do not automatically apply to compounded ketamine. But the comparison shows what FDA is focused on when ketamine products are marketed for psychiatric use: legitimate prescribing, clinical supervision, and patient monitoring safeguards.

· Compounding Is a Pathway, Not a Label: This is where the warning letters become especially relevant for compounding pharmacies, outsourcing facilities, manufacturers, and distributors. FDA did not state that ketamine may never be compounded. It found that certain sellers were offering products described as “professionally compounded” without satisfying the conditions necessary to qualify under Section 503A or Section 503B. For a 503A product, that includes compounding by an authorized pharmacist or physician and, as relevant here, receipt of a valid prescription for an individually identified patient. For a 503B product, the drug must be compounded by or under the direct supervision of a licensed pharmacist in a registered outsourcing facility, and the statute restricts resale or transfer by an entity other than the outsourcing facility that compounded it. Calling a product “compounded” cannot convert ordinary manufacturing, online retailing, or third-party distribution into a compliant compounding pathway.

· Prescription Bypass: FDA repeatedly focused on websites that allowed consumers to purchase prescription ketamine products without a prescription. This was not treated as a minor checkout problem. FDA characterized it as misbranding and a direct patient-safety issue.

· Bypassing Natural Defenses: FDA also called out the heightened contamination risk associated with injectable drug products. Because injectables bypass the body’s natural defenses, contaminated or improperly manufactured products can lead to serious and life-threatening conditions, including septicemia or sepsis.

“Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.” — U.S. Food and Drug Administration

We are currently witnessing a massive cultural shift toward the acceptance of ketamine for treatment-resistant depression, PTSD, and anxiety. Legitimate telehealth platforms and clinical networks have done incredible work expanding access to these life-changing therapies safely. That may include lawful off-label prescribing of FDA-approved ketamine by licensed practitioners, use of SPRAVATO within its approved indications and REMS, and compounded ketamine prepared and distributed through a model that satisfies Section 503A or 503B, as applicable. The warning letters do not say that legitimate, prescriber-led ketamine care or properly structured compounding is unlawful.

However, this high demand has created a parallel dark market. When platforms look identical to clean, modern direct-to-consumer healthcare brands but completely skip medical triaging and prescriptions, consumer safety plummets. The fact that a website looks clinical does not mean the product, prescriber, pharmacy, or supply chain is compliant.

Ten warning letters issued on the same day, following website reviews conducted over several months, look like a coordinated enforcement effort rather than a one off. Most of the letters direct the companies to respond to FDA’s Internet Pharmacy Task Force. That tells the industry how FDA is framing the problem: unlawful online distribution of prescription drugs, not ordinary off-label prescribing within a legitimate clinical relationship.

For legitimate operators in the behavioral health and psychedelic space, this enforcement is actually good news. It begins to separate compliance-focused, medically supervised clinics and telehealth networks from outright illegal supply chains. It is also a compliance checklist. Who is prescribing? Who is compounding or dispensing? Is the pharmacy properly licensed? Does the product actually fit within Section 503A or 503B? What claims appear on the website? Can the consumer complete a purchase without a valid prescription?

Ketamine businesses should review their website claims, prescribing workflow, pharmacy relationships, product sourcing, dispensing model, and patient-monitoring protocols before FDA or a state regulator does it for them.

The bottom line: Ketamine is not going away. Neither is FDA scrutiny. As public interest grows, regulatory scrutiny will grow right alongside it. True innovation in mental health care cannot survive without clinical integrity. Storefronts trying to commoditize controlled substances without medical oversight are officially on borrowed time.